Back
32
26
Day Range
$27.00
$27.00
52-Week Range
$20.03
$27.00
Volume
2,500
50D / 200D Avg
$26.41
/
$24.68
Prev Close
$27.00
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 21.7 | 0.3 |
| P/B | 3.6 | 2.9 |
| ROE % | 17.3 | 3.7 |
| Net Margin % | 9.6 | 3.8 |
| Rev Growth 5Y % | 13.5 | 10.0 |
| D/E | 0.9 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2029 |
$2.41
$2.32 – $2.49
|
1.5 B | 1 |
| FY2028 |
$1.85
$1.78 – $1.91
|
1.3 B | 1 |
| FY2027 |
$1.60
$1.54 – $1.66
|
1.2 B | 1 |
Key Takeaways
Revenue grew 13.49% annually over 5 years — strong growth
ROE of 17.29% — decent returns on equity
Generating 112.98M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.33%
Cash machine — converts 124.18% of earnings into free cash flow
Capital efficient — spends only 1.60% of revenue on capex
Growth
Revenue Growth (5Y)
13.49%
Revenue (1Y)9.16%
Earnings (1Y)12.95%
FCF Growth (3Y)14.51%
Quality
Return on Equity
17.29%
ROIC10.30%
Net Margin9.56%
Op. Margin15.36%
Safety
Debt / Equity
0.93
Current Ratio2.11
Interest Coverage4.47
Valuation
P/E Ratio
21.73
P/B Ratio3.59
EV/EBITDA15.77
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9.16% | Revenue Growth (3Y) | 11.69% |
| Earnings Growth (1Y) | 12.95% | Earnings Growth (3Y) | 13.57% |
| Revenue Growth (5Y) | 13.49% | Earnings Growth (5Y) | 10.51% |
| Profitability | |||
| Revenue (TTM) | 951.81M | Net Income (TTM) | 90.99M |
| ROE | 17.29% | ROA | 7.32% |
| Gross Margin | 15.25% | Operating Margin | 15.36% |
| Net Margin | 9.56% | Free Cash Flow (TTM) | 112.98M |
| ROIC | 10.30% | FCF Growth (3Y) | 14.51% |
| Safety | |||
| Debt / Equity | 0.93 | Current Ratio | 2.11 |
| Interest Coverage | 4.47 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 21.73 | P/B Ratio | 3.59 |
| P/S Ratio | 2.08 | PEG Ratio | 1.26 |
| EV/EBITDA | 15.77 | Dividend Yield | 0.02% |
| Market Cap | 1.98B | Enterprise Value | 2.31B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 951.81M | 871.96M | 762.99M | 683.88M | 573.81M |
| Net Income | 90.99M | 80.55M | 70.55M | 69.61M | 61.00M |
| EPS (Diluted) | 1.24 | 1.10 | 0.97 | 0.96 | 0.84 |
| Gross Profit | 145.13M | 395.68M | 332.61M | 286.17M | 247.50M |
| Operating Income | 146.16M | 130.70M | 108.63M | 97.91M | 87.44M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1.24B | 1.08B | 1.01B | 971.01M | 800.42M |
| Total Liabilities | 686.62M | 578.16M | 539.33M | 562.38M | 474.96M |
| Shareholders' Equity | 551.40M | 501.35M | 463.75M | 402.66M | 320.11M |
| Total Debt | 512.59M | 385.70M | 366.74M | 399.38M | 335.59M |
| Cash & Equivalents | 184.83M | 115.04M | 133.01M | 125.34M | 70.65M |
| Current Assets | 462.67M | 362.56M | 335.90M | 318.01M | 233.71M |
| Current Liabilities | 218.90M | 194.71M | 175.26M | 171.01M | 145.06M |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#799 of 1052
Custom
Balanced Risk
#144 of 151
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026
Entered
Balanced Risk
Mar 24, 2026